| Bioactivity | SARS-CoV-2 Mpro-IN-17 (compound S5-28) is an orally active and noncovalent SARS-CoV-2 Mpro inhibitor with the EC50 of 1.35 μM. SARS-CoV-2 Mpro-IN-17 can be used for study of COVID-19[1]. |
| Formula | C20H19BrClN3O2 |
| Molar Mass | 448.74 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Gao Q, et al. Discovery of meisoindigo derivatives as noncovalent and orally available Mpro inhibitors: their therapeutic implications in the treatment of COVID-19. Eur J Med Chem. 2024;273:116498. |
SARS-CoV-2 Mpro-IN-17
CAS: F: C20H19BrClN3O2 W: 448.74
SARS-CoV-2 Mpro-IN-17 (compound S5-28) is an orally active and noncovalent SARS-CoV-2 Mpro inhibitor with the EC50 of 1.
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.